Clinical trial
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
NCT01915576 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
- Lead sponsor
- Bayer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2013
- Completion date
- December 31, 2016
- Enrollment
- 79 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.